// App-Quantinova.ai

147 : Efficacy and Safety of LY2951742 in a Randomized, Double-blind, Placebo-controlled, Dose-ranging Study in Patients with Migraine

Researchers

Presenter

  • Tina Oakes

Principal Investigators

  • Qi Zhang

  • Margaret Ferguson

  • Vladimir Skljarevski

  • James Martinez

  • Kirk Johnson

  • Aaron Schacht

  • Michael Due

  • Peter Goadsby

  • David Dodick

  • Colin Zappone

Medical Centers

  • Eli Lilly and Company, Indianapolis, IN

  • Kings College London, London, UK

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Migraine

Biomarkers

  • N/A

Drug/Treatment

  • LY2951742

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Superiority

  • Controlled

Phase

  • NA

Study Id's

  • NCT02163993

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved